Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Zoledronic acid (ZA) has been shown to inhibit prostate tumor growth in vitro and have beneficial effects in patients with advanced prostate cancer (CaP). The aim of this study was to determine whether ZA exhibits direct anti-tumor effects on CaP cells in vivo. To distinguish the effects of inhibition of osteolysis and direct anti-tumor activity of ZA in vivo, we compared the results of treatment with ZA and osteoprotegerin (Fc-OPG), which inhibits osteolysis, but without significant direct anti-tumor effects. In vitro Fc-OPG had no significant effects on C4-2 proliferation, whereas ZA decreased proliferation. However, both agents decreased tumor growth in bone. Moreover, both increased bone volume and prevented the overall decreases in BMD associated with growth of C4-2 cells in bone. Our study provides novel and significant observations that the in vivo effects of ZA are consistent with indirect effects mediated by osteoclasts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the experimental use of OPG in numerous bone metastasis models has provided substantial evidence that turnover suppression is the principal means by which bisphosphonates and RANKL inhibitors reduce skeletal tumor burden (340,(343)(344)(345).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
In the citing paper
“Although OPG had no significant effects on the proliferation of cultured C4 -2 cells, high doses of ZOL (10 -100 m) were associated with significant C4 -2 growth suppression.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
In the citing paper
“OPG and ZOL both significantly decreased skeletal tumor burden when delivered in a preventative manner, whereas only OPG caused significant suppression of skeletal tumor burden when treatment was delayed until lytic tumors were established (344).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
In the citing paper
“OPG and ZOL both suppressed tumor-associated osteolysis and decreased osteoclast surfaces in tumor-bearing bones (344).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Self-citationBisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee, M. V., Fong, E. D. M., Singer, F. R., & Guenette, R. S. (2001) · PubMed · Cited by 364
Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 318
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Zheng, Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J. R. K., Seibel, M. J., & Dunstan, C. R. (2007) · Bone · doi:10.1016/j.bone.2006.09.016 · Cited by 82
Miller, R. E., Roudier, M. P., Jones, J. C., Armstrong, A. P., Canon, J. R., & Dougall, W. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0046 · Cited by 85
Brubaker, K. D., Brown, L. G., Vessella, R. L., & Corey, E. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-15 · Cited by 80
Self-citationThe role of the bone microenvironment in skeletal metastasis
Zheng, Y., Zhou, H., Dunstan, C., Sutherland, R., & Seibel, M. (2012) · Journal of Bone Oncology · doi:10.1016/j.jbo.2012.11.002 · Cited by 79
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis
Lipton, A., & Goessl, C. D. (2010) · Bone · doi:10.1016/j.bone.2010.10.161 · Cited by 78
Vessella, R. L., & Corey, E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0813 · Cited by 71
Self-citationUnderstanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Sottnik, J. L., & Keller, E. T. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040012 · Cited by 67
Self-citationMorgan, T. M., Pitts, T. E. M., Gross, T. S., Poliachik, S. L., Vessella, R. L., & Corey, E. (2008) · The Prostate · doi:10.1002/pros.20752 · Cited by 62
Self-citationRegulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
Lamoureux, F., Moriceau, G., Picarda, G. G. A., Rousseau, J., Trichet, V., & Rédiní, F. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.004 · Cited by 50
Duivenvoorden, W., Vukmirović-Popović, S., Kalina, M., Seidlitz, E. P., & Singh, G. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603740 · Cited by 39
“The main target of zoledronic acid appears to be the induction of apoptosis (Corey et al, 2003; Quinn et al, 2005), whereas doxycycline induces a G1 cell cycle arrest (Van den Bogert et al, 1986).”
BackgroundMorrissey, C. M., Kostenuik, P. J., Brown, L. G., Vessella, R. L., & Corey, E. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-148 · Cited by 37
Self-citationChang, J., Wang, W., Zhang, H., Hu, Y., & Yin, Z. (2012) · Oncology Letters · doi:10.3892/ol.2012.723 · Cited by 41
“All of these findings suggest the potential involvement of the RANK/RANKL/OPG axis in osteosarcoma (28).”
Cancer Interaction with the Bone Microenvironment
Cher, M. L., Towler, D. A., Rafii, S., Rowley, D. R., Donahue, H. J., Keller, E. T., Herlyn, M., Cho, E. A., & Chung, L. W. K. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050874 · Cited by 39
“Another bisphosphonate, zoledronic acid, appears to target prostate cancer cells directly in addition to diminishing osteoclast activity at the metastatic site.(26) In addition to bisphosphonates, other novel therapies based on studies delineating the mechanisms of skeletal metastases will certainly be developed in th…”
BackgroundSelf-citationHung, T., Chan, J. C. H., Russell, P. J., & Power, C. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019389 · Cited by 33
“These results are in agreement with previous reports of decreased osteocalcin in breast cancer patients [19] and a TRAP 5b decrease in mice [20] Figure 5.”
ResultRANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model
Ignatoski, K. M. W., Escara-Wilke, J. F., Dai, J., Lui, A., Dougall, W. C., Daignault, S. D., Yao, Z., Zhang, J., Day, M. L., Sargent, E., et al. (2008) · The Prostate · doi:10.1002/pros.20744 · Cited by 28
Self-citationDai, J., Lu, Y., Yu, C., Keller, J. M., Mizokami, A., Zhang, J., & Keller, E. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0100 · Cited by 29
Self-citationThe association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer
Omar, H. S., Shaker, O. G., Nassar, Y. H., Marzouk, S., & Elmarzouky, M. S. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2352-z · Cited by 24
Yin, J., Wang, L., Tang, W., Wang, X., Lv, L., Shao, A., Shi, Y., Ding, G., Chen, S., & Gu, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101705 · Cited by 16
Bone Directed Therapies for Prostate Cancer
Bradley, D., Hussain, M., DiPaola, R. S., & Kantoff, P. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.04.035 · Cited by 15
Molecular treatment strategies and surgical reconstruction for metastatic bone diseases
Zou, X., Zou, L., He, Y., & Bünger, C. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.012 · Cited by 15
“Despite the direct inhibitory effects of bisphosphonates on cancer cells in vitro, the inhibition of cancer growth in vivo primarily attributes to indirect effects related to decreased bone lysis.(15) Moreover, a new generation bisphosphonate, zoledronic acid exhibits direct effect on osteoblasts, altering expression…”
BackgroundCody, J. J., Rivera, Á. A., Lyons, G. R., Yang, S. W., Wang, M., Ashley, J. W., Meleth, S., Feng, X., Siegal, G. P., & Douglas, J. T. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2012.179 · Cited by 3
“These include studies in which OPG expression within a prostate cancer bone lesion inhibited both osteoblastic (19) and osteolytic (48) tumor progression and others involving the use of recombinant OPG (17, 18, 20, 53, 56) in intratibial models of prostate bone metastases.”
Huang, Q., & Ouyang, X. (2013) · The International Journal of Biological Markers · doi:10.5301/jbm.5000022 · Cited by 2
Curriculum Vitae Personal Data
Selmeczi, D. (2008) · Cited by 2
Liao, F., Liu, S.-B., Liu, Y., Liu, H., Hu, J., & Liu, X. (2018) · PubMed Central · doi:10.7518/hxkq.2018.04.004 · Cited by 1
Tumor-Bone Cell Interactions in Bone Metastases
Fournier, P. G. J., Dunn, L. K., Clines, G. A., & Guise, T. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00002-5 · Cited by 3
RANKL: Targeting bone and cancer to treat skeletal complications of malignancy
Crook, M. K., & Guise, T. A. (2009) · IBMS BoneKEy · doi:10.1138/20090396 · Cited by 1
2006 Conference on Innovations and Challenges in Prostate Cancer
(2007) · The Journal of Urology · doi:10.1016/j.juro.2007.06.004
Metadata
- Authors
- Quinn, J. E., Brown, L. G., Zhang, J., Keller, E. T., Vessella, R. L., & Corey, E.
- Affiliations
- University of Washington (US)
- University of Michigan (US)
- Corresponding author
- Corey, E
- Venue
- Prostate Cancer and Prostatic Diseases
- Published
- 2005-07-05
- Volume
- 8
- Issue
- 3
- Pages
- 253-259
- ISSN
- 1365-7852 (ISSN-L)
- 1476-5608
- OpenAlex
- W2027402812
- Cited by
- 29
- References
- 26
- Citations by year
- 2018: 1 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 3
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Prostate Cancer and Prostatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Amgen
- Novartis
- National Institutes of Health
- Novartis Pharma
- National Cancer Institute (P01 CA85859-01A, P01CA085859)
- DOD Prostate Cancer Research Program
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- zoledronic acid, prostate cancer, bone metastasis, osteolysis, osteoclasts, tumor cell proliferation, bone volume, bone mineral density, bisphosphonates
- MeSH terms
- Zoledronic Acid, Animals, Antibodies, Antineoplastic Agents, Bone Neoplasms, Densitometry, Diphosphonates, Glycoproteins, Humans, Imidazoles, Immunoglobulin Fc Fragments, Male, Neoplasm Metastasis, Osteoclasts, Osteolysis, Prostatic Neoplasms, Tibia, Time Factors, Bone Density, Mice, SCID, Apoptosis, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Cell Proliferation, Bone Density Conservation Agents, Mice, Osteoprotegerin, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.